
Opinion|Videos|April 18, 2025
Monitoring and Setting Treatment Expectations With JAK Inhibitors in Alopecia Areata
Author(s)Arash Mostaghimi, MD, MPH, Brett King, MD, PhD
A panelist discusses how they determine the appropriateness of a Janus kinase (JAK) inhibitor for patients by evaluating disease severity, duration, prior treatment failures, patient comorbidities, risk factors, and laboratory results and engaging in detailed benefit-risk discussions while setting realistic expectations about treatment outcomes and potential adverse effects.
Advertisement
Episodes in this series

How do you decide whether a JAK inhibitor is an appropriate treatment option for a patient?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
FDA News Recap: Novel Drug Approvals in Q2 2026
2
8 Pulmonology Headlines you Missed in Q2 2026
3
9 Cardiology Headlines You Missed in Q2 2026
4
FDA Expands Exa-Cel Gene Therapy Approval to Children 2 Years and Up With SCD or β-Thalassemia
5
















































































